In summary, our data demonstrates that DPPIV inhibition with sitagliptin can prevent cardiac fibrosis and attenuate the cardiac hypertrophy and diastolic dysfunction in an experimental model of CKD. Here, DPP4 is linked to chronic kidney disease.